Vaxart, Inc.
VXRT
Rank in Stocks
#20203
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Share Price
$0.3661
Last synced: 2026-11-09
Market Cap
$88.90M
Change (1 day)
-1.05%
Change (1 year)
-1.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vaxart, Inc. (VXRT)
Category
Healthcare
Operating Margin for Vaxart, Inc. (VXRT)
Operating Margin as of November 2026 TTM: 16.30%
According to Vaxart, Inc.'s latest financial reports, its current operating margin (TTM) is 16.30%. At the end of 2025 the company had an operating margin of 7.62%.
Operating Margin history for Vaxart, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 16.30% | 113.91% |
| 2025 | 7.62% | -103.30% |
| 2024 | -230.99% | -79.55% |
| 2023 | -1,129.52% | -98.95% |
| 2022 | -107,090.65% | 1,213.02% |
| 2021 | -8,156.05% | 993.79% |
| 2020 | -745.67% | 365.87% |
| 2019 | -160.06% | -69.40% |
| 2018 | -523.11% | 235.09% |
| 2017 | -156.11% | -42.39% |
| 2016 | -270.97% | 241.83% |
| 2015 | -79.27% | 373.54% |
| 2014 | -16.74% | -74.55% |
| 2013 | -65.77% | -0.03% |
| 2011 | -65.79% | 1,823.68% |
| 2010 | -3.42% | -98.00% |
| 2009 | -171.38% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | -100.00% |
| 2006 | -68.23% | -39.89% |
| 2005 | -113.50% | 210.11% |
| 2004 | -36.60% | 400.68% |
| 2003 | -7.31% | -490.91% |
| 2002 | 1.87% | -96.25% |
| 2001 | 49.83% | 3,073.89% |
| 2000 | 1.57% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -97.63% |
US
|
|
| -149.01% | -109.14% |
US
|
|
| 25.57% | -98.43% |
AU
|
|
| 31.23% | -98.08% |
BE
|
|
| 29.35% | -98.20% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Vaxart, Inc.'s operating margin
What is Vaxart, Inc.'s operating margin?
Vaxart, Inc.'s operating margin is 16.30%, as of Nov 2026.
What was Vaxart, Inc.'s operating margin in 2025?
In 2025, Vaxart, Inc.'s operating margin was 7.62%, compared with -230.99% in 2024.
How has Vaxart, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Vaxart, Inc.'s operating margin was highest in 2025 (7.62%) and lowest in 2022 (-107,090.65%).
How does Vaxart, Inc.'s operating margin compare with similar companies?
Vaxart, Inc.'s operating margin (16.30%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.